Phaseline

Companies › RECORDATI GROUP

RECORDATI GROUP: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 2 Phase 4, 2 Phase 2; Metabolic and endocrine, Cardiovascular; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Osilodrostat (LCI699)
Cytochrome P450 11B1 inhibitor
CYP11B1Phase 4Hypertension; Cushing Syndrome; Mild Autonomous Cortisol Secretion (MACS)Jul 2027
Pasireotide Diaspartate
Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 1 agonist
SSTR5, SSTR2, SSTR1, SSTR3Phase 2Post-Bariatric Hypoglycemia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05928390Pasireotide DiaspartatePhase 2Post-Bariatric HypoglycemiaMetabolic and endocrineOct 2026
NCT03708900Osilodrostat (LCI699)Phase 2Cushing SyndromeMetabolic and endocrineJul 2027
NCT07268222Osilodrostat (LCI699)Phase 4Mild Autonomous Cortisol Secretion (MACS)Metabolic and endocrineNov 2027
NCT07247162Osilodrostat (LCI699)Phase 4HypertensionCardiovascularMay 2028

From the company's SEC filings

Complete response letters from FDA

Targets

CYP11B1 (1) SSTR5 (1) SSTR2 (1) SSTR1 (1) SSTR3 (1)

Companies with the same targets

Novartis Sinotau Pharmaceutical Group HTA RayzeBio Advanced Accelerator Applications CSPC ZhongQi Pharmaceutical Technology ITM Solucin Debiopharm International Actinogen Medical H. Lundbeck

Companies built like this

Kailera Crystalys Therapeutics Vincentage Pharma Rhythm Pharmaceuticals Rare Thyroid Therapeutics International

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.